About 44,053 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  13,133 results

Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelod...
Clinical and Experimental Medicine; Oh S, Kim E

Mar 26th, 2023 - Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies that mostly affect the elderly and have poor prognoses. Mutations in epigenetic regulatory genes cause AML/MDS through changes in DNA methylation and his...

Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromoso...
International Journal of Hematology; Fukushima H, Morita K et. al.

Mar 26th, 2023 - Acute pancreatitis is an acute inflammatory process of the pancreas that is becoming an increasingly common clinical issue. The most frequent underlying etiologies include gallstones and chronic alcohol use, which account for more than two-thirds ...

RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.
Leukemia & Lymphoma; Xiao J, Xie J et. al.

Mar 26th, 2023 - We retrospectively explored the prognostic impact of DAT mutations at diagnosis in 122 RUNX1mut AML patients. RUNX1 missense mutation was dominant in the RUNT domain, and frameshift mutation was dominant in the TAD domain. DAT mutations occurred i...

Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Current Treatment Options in Oncology; Wang C, Sallman DA

Mar 26th, 2023 - Lower risk myelodysplastic syndromes are typically characterized by an indolent disease course with a relatively low risk of transformation into acute myeloid leukemia. These patients are classically identified using the revised International Prog...

Recent advances in targeted therapies in acute myeloid leukemia.
Journal of Hematology & Oncology; Bhansali RS, Pratz KW et. al.

Mar 26th, 2023 - Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem c...

see more →

Guidelines  13 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  33 results see all →

Clinicaltrials.gov  1,760 results

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Mar 24th, 2023 - The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT).

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Mar 24th, 2023 - The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies

Mar 22nd, 2023 - Older people with cancer differ from younger patients due to the combined effects of aging, comorbidities and cancer treatments on their health. In acute myeloid leukemia (AML) and non-hodgkin lymphoma (NHL), chemotherapy, which is the main treatm...

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

Mar 17th, 2023 - This is a phase II study that seeks to treat patients ages 18-59 who have acute myeloid leukemia but have never been treated before. It will use venetoclax and azacitidine, and patients can receive up to four cycles of this medication. Depending o...

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Mar 16th, 2023 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of the combination of decitabine and cedazuridine (ASTX727), venetoclax and gilteritinib in patients with relapsed/refractory FLT3- mutated acute myeloid leukemia (AML) or high-r...

see more →

News  2,666 results

Jimmy Carter's Melanoma; Post-Op Osimertinib Boosts OS; $83K for Unproven Therapy

Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...

Maternal Infection May Play Role in Child's Leukemia

Feb 20th, 2023 - Maternal genitourinary tract infections during pregnancy were linked to the development of leukemia in offspring, a Danish nationwide study found. Children born to a mother who experienced any kind of infection during pregnancy had increased risk ...

Toxin Exposure and Acute Myeloid Leukemia in Veterans
Timothy O'Brien, MD

Feb 8th, 2023 - Members of the United States military who served in Vietnam between 1961 and 1971 risked exposure to the weaponized chemical defoliant known as Agent Orange. Among the components of Agent Orange, benzene and tetrachlorodibenzo-p-dioxin (TCDD) are.

ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies

Jan 27th, 2023 - The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B-cell lymphoma. Jansse...

Rise in Cervical Cancer Mortality; Drug Active in Kids' Glioma; Vit D and Melanoma

Jan 13th, 2023 - A California study showed a concerning increase in cervical cancer mortality among women 65 or older, the age at which routine screening is no longer recommended. (UC Davis Comprehensive Cancer Center, Cancer Epidemiology, Biomarkers & Prevention)...

see more →

Patient Education  16 results see all →